Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists
Kengo Shimono, Wei-En Tung, Christine Macolino, Amber Hsu-Tsai Chi, Johanna H Didizian, Christina Mundy, Roshantha A Chandraratna, Yuji Mishina, Motomi Enomoto-Iwamoto, Maurizio Pacifici, Masahiro Iwamoto, Kengo Shimono, Wei-En Tung, Christine Macolino, Amber Hsu-Tsai Chi, Johanna H Didizian, Christina Mundy, Roshantha A Chandraratna, Yuji Mishina, Motomi Enomoto-Iwamoto, Maurizio Pacifici, Masahiro Iwamoto
Abstract
Heterotopic ossification consists of ectopic bone formation within soft tissues after surgery or trauma. It can have debilitating consequences, but there is no definitive cure. Here we show that heterotopic ossification was essentially prevented in mice receiving a nuclear retinoic acid receptor-γ (RAR-γ) agonist. Side effects were minimal, and there was no significant rebound effect. To uncover the mechanisms of these responses, we treated mouse mesenchymal stem cells with an RAR-γ agonist and transplanted them into nude mice. Whereas control cells formed ectopic bone masses, cells that had been pretreated with the RAR-γ agonist did not, suggesting that they had lost their skeletogenic potential. The cells became unresponsive to rBMP-2 treatment in vitro and showed decreases in phosphorylation of Smad1, Smad5 and Smad8 and in overall levels of Smad proteins. In addition, an RAR-γ agonist blocked heterotopic ossification in transgenic mice expressing activin receptor-like kinase-2 (ALK2) Q207D, a constitutively active form of the receptor that is related to ALK2 R206H found in individuals with fibrodysplasia ossificans progressiva. The data indicate that RAR-γ agonists are potent inhibitors of heterotopic ossification in mouse models and, thus, may also be effective against injury-induced and congenital heterotopic ossification in humans.
Figures
References
- Chalmers J, Gray DH, Rush J. Observation on the induction of bone in soft tissues. J Bone Joint Surg Br. 1975;57:36–45.
- Garland DE. A clinical prospective on common forms of acquired heterotopic ossification. Clin Orthop. 1991;263:13–29.
- Nilsson OS, Persson PE. Heterotopic bone formation after joint replacement. Curr Opin Rheumatol. 1999;11:127–131.
- Forsberg JA, et al. Heterotopic ossification in high-energy wartime extremity injuries: prevalence and risk factors. J Bone Joint Surg. 2009;91:1084–1091.
- McCarthy EF, Sundaram M. Heterotopic ossification: a review. Skeletal Radiol. 2005;34:609–619.
- Vanden Booshe L, Vanderstraeten G. Heterotopic ossification: a review. J Rehabil Med. 2005;37:129–136.
- Pignolo RJ, Suda RK, Kaplan FS. The fibrodysplasia ossificans progressiva lesion. Clin Rev Bone Min Met. 2005;5:195–200.
- Shore E, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genet. 2006;38:525–527.
- Chao ST, Joyce MJ, Suh JH. Treatment of heterotopic ossification. Orthopedics. 2007;30 :457–464.
- Kaplan FS. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Clin Proc Intl Clin Consort FOP. 2008;3:1082.
- Fukuda T, et al. Generation of a mouse with conditionally activated signaling through the BMP receptor, ALK2. Genesis. 2006;44:159–167.
- Zhang D, et al. ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development. J Bone Min Res. 2003;18:1593–1604.
- Yu PB, Deng DY, et al. BMP type I receptor inhibition reduces heterotopic ossification. Nat Med. 2008;14:1363–1369.
- Shimono K, et al. Inhibition of ectopic bone formation by a selective retinoic acid receptor α-agonist: a new therapy for heterotopic ossification? J Orthop Res. 2010;28:271–277.
- Pacifici M, Cossu G, Molinaro M, Tato' F. Vitamin A inhibits chondrogenesis but not myogenesis. Exp Cell Res. 1980;129:469–474.
- Weston AD, Chandraratna RAS, Torchia J, Underhill TM. Requirement for RAR-mediated gene repression in skeletal progenitor differentiation. J Cell Biol. 2002;158:39–51.
- Weston AD, Hoffman LM, Underhill TM. Revisiting the role of retinoid signaling in skeletal development. Birth Defects Research Pt C. 2003;69:156–173.
- Rochette-Egly C, Germain P. Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors (RARs) Nuclear Rec Signal. 2009;7:1–18.
- Koyama E, et al. Retinoid signaling is required for chondrocyte maturation and endochondral bone formation during limb skeletogenesis. Dev Biol. 1999;208:375–391.
- Williams JA, et al. Retinoic acid receptors are required for skeletal growth, matrix homeostasis and growth plate function in postnatal mouse. Dev Biol. 2009;328:315–327.
- Tacher SM, Vasudevan J, Chandraratna RAS. Therapeutic applications for ligands of retinoic receptors. Curr Pharmaceut Design. 2000;6:25–58.
- O'Connor JP. Animal models of heterotopic ossification. Clin Orth Relat Res. 1998;346:71–80.
- Gehin M, et al. Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem Biol. 1999;6:519–529.
- Keidel S, LeMotte P, Apfel C. Different agonist- and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping. Mol Biol Cell. 1994;14:287–298.
- Klein ES, et al. Identification and functional separation of retinoic acid receptor neutral antagonists and inverse agonists. J Biol Chem. 1996;271:22692–22696.
- Bernard BA, et al. Identification of synthetic retinoids for selectivity for human nuclear retinoic acid receptor γ. Biochem Biophys Res Commun. 1992;186:977–983.
- Hind M, Stinchcombe S. Palovarotene, a novel retinoic acid receptor gamma agonist for the treatment of emphysema. Curr Opin Invest Drugs. 2009;10:1243–1250.
- Blaner WS, Olson JA. In: The retinoids: Biology, Chemistry, and Medicine. Sporn MB, Roberts AB, Goodman DS, editors. Raven Press; 1994. pp. 229–255.
- Zasloff MA, Rocke DM, Crofford LJ, Hahn GV, Kaplan FS. Treatment of patients who have fibrodysplasia ossificans progressiva with isotretinoin. Clin Orthop. 1998;346:121–129.
- DeSimone DP, Reddi AH. Influence of vitamin A on matrix-induced endochondral bone formation. Calcif Tissue Int. 1983;35:732–739.
- Shen Q, et al. The fibrodysplasia ossificans progressiva R206H ACVRa mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J Clin Invest. 2009;119:3462–3472.
- Korchynskyi O, ten Dijke P. Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem. 2002;277:4883–4891.
- Massague J. TGF-β signal transduction. Annu Rev Biochem. 1998;67:753–791.
- Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in the TGF-β family signaling. Nature. 2003;425:577–584.
- Otsuru S, et al. Osteopoietic engraftment after bone marrow transplantation: effect of imbred strain of mice. Exp Hematol. 2010;38:836–844.
- Hoffman LM, et al. BMP action in skeletogenesis involves attenuation of retinoid signaling. J Cell Biol. 2006;174:101–113.
- Pendaries V, Verrecchia F, Michel S, Mauviel A. Retinoic acid receptors interfere with the TGF-β/Smad signaling pathway in a ligand-specific manner. Oncogene. 2003;22:8212–8220.
- Yasuhara R, et al. Wnt/β-catenin and retinoic acid receptor signaling pathways interact to regulate chondrocyte function and matrix turnover. J Biol Chem. 2010;285:317–327.
- Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005;8:739–750.
- Tamamura Y, et al. Developmental regulation of Wnt/β-catenin signals is required for growth plate assembly, cartilage integrity, and endochondral ossification. J Biol Chem. 2005;280:19185–19195.
- Nozaki Y, et al. Anti-inflammatory effect of all-trans-retinoic acid in inflammatory arthritis. Clin Immunol. 2006;119:272–279.
- Benglis D, Wang MY, Levi AD. A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery. Oper Neurosurg. 2008;62:423–431.
- Shao JS, Cai J, Towler DA. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol. 2006;26:1423–1430.
- Bone LB, Johnson KD, Weigelt J, Scheinberg R. Early versus delayed stabilization of femural fractures. A prospective randomized study. J Bone Joint Surg. 1989;71 :336–340.
- Kakudo N, Kausumoto K, Wang YB, Iguchi Y, Ogawa Y. Immunolocalization of vascular endothelial growth factor on intramuscular ectopic osteoinduction by bone morphogenetic pprotein-2. Life Sci. 2006;79:1847–1855.
Source: PubMed